TD Asset Management
JANX icon

TD Asset Management’s Janux Therapeutics JANX Stock Holding History

TD Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,006
Closed -$235K – 1261
2025
Q4 		$235K Sell
17,006
-75,296
-82% -$1.77M ﹤0.01% 1210
2025
Q3 		$2.26M Buy
92,302
+27,066
+41% +$659K ﹤0.01% 938
2025
Q2 		$1.51M Sell
65,236
-400
-0.6% -$10.5K ﹤0.01% 997
2025
Q1 		$1.77M Sell
65,636
-13,200
-17% -$498K ﹤0.01% 994
2024
Q4 		$4.22M Buy
78,836
+69,302
+727% +$3.67M ﹤0.01% 827
2024
Q3 		$441K Sell
9,534
-10,266
-52% -$447K ﹤0.01% 1313
2024
Q2 		$829K Buy
+19,800
New +$930K ﹤0.01% 1194

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TD Asset Management's JANX Position: Q1 2026 in Review

TD Asset Management sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 17,006 shares — an estimated $235K sold.

TD Asset Management first reported a position in JANX in Q2 2024 and held it in 7 quarters. The position peaked at $4.22M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • TD Asset Management reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 17,006 Janux Therapeutics shares in Q1 2026, an estimated $235K.
  • TD Asset Management first reported a position in Janux Therapeutics in Q2 2024 and held it in 7 quarters.
  • TD Asset Management's Janux Therapeutics position peaked at $4.22M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.